Currently, monoclonal antibodies such as dupilumab (anti-IL-4Rα), omalizumab (anti-IgE), mepolizumab (anti-IL-5), and benralizumab (anti-IL-5R) are approved for CRSwNP treatment, particularly in cases of the inadequately controlled disease. Here, IGHE is linked to chronic rhinosinusitis with nasal polyps.